Se estima que el tamaño del mercado de pruebas de cáncer hereditario alcanzará los 9.840,52 millones de dólares en 2027, frente a los 3.967,74 millones de dólares de 2018; se espera que crezca a una tasa compuesta anual del 11,1 % durante 2019-2027.
Un cáncer hereditario es cualquier cáncer causado por una mutación genética hereditaria. Se sabe que las variantes dañinas en algunos genes están asociadas con un mayor riesgo de desarrollar cáncer. Las pruebas genéticas ayudan a estimar las posibilidades de que un individuo desarrolle cáncer a lo largo de su vida. Esto se puede hacer buscando mutaciones en los genes, cromosomas o proteínas de cada uno. Hay pruebas genéticas disponibles para algunos tipos de cáncer. Estos incluyen cáncer de mama, cáncer de ovario, cáncer de colon, cáncer de tiroides, cáncer de próstata, cáncer de páncreas, melanoma, sarcoma, cáncer de riñón y cáncer de estómago.
La tendencia del mercado de pruebas de cáncer hereditario se atribuye a un mayor enfoque en la I+D de pruebas genéticas para analizar la correlación del cáncer con la secuencia genética, aumentando la prevalencia. de cáncer hereditario y el aumento de la demanda de kits de pruebas de ADN. Sin embargo, las estrictas regulaciones sobre el diagnóstico del cáncer pueden obstaculizar el crecimiento del mercado.
Perspectivas estratégicas
regiones lucrativas para el cáncer hereditario Pruebas de mercado
Perspectivas del mercado
Prevalencia creciente del cáncer hereditario
El cáncer es una enfermedad genética Trastorno causado por variaciones definidas en los genes que gobiernan el funcionamiento de las células, afectando particularmente su crecimiento y replicación. Las mutaciones genéticas hereditarias son la causa de entre el 5 y el 10 % de todos los cánceres. Los investigadores han relacionado mutaciones en genes particulares con más de 50 síndromes de cáncer hereditario que afectan a los individuos en el desarrollo de ciertos cánceres. Según la Organización Mundial de la Salud, el cáncer causó ~9,6 millones de muertes en todo el mundo en 2018. Además, según la predicción del Instituto Nacional del Cáncer, en 2018, se diagnosticarían ~1.735.350 nuevos casos de cáncer en los EE. UU. La creciente prevalencia del cáncer de mama en el mundo es una gran preocupación. Según la Organización Mundial de la Salud, en 2018 se notificaron ~2,09 millones de casos de cáncer de mama en todo el mundo. Sin embargo, según breastcancer.org, en 2018, más de 3,1 millones de mujeres en los EE. UU. tenían antecedentes de cáncer de mama.
Además, entre el 5 y el 10 % de los cánceres de mama están relacionados con genes mutados heredados de los padres. Las variaciones en los genes BRCA1 y BRCA2 son prevalentes. Las mujeres con una mutación BRCA1 tienen ~72 % de riesgo de desarrollar cáncer de mama a lo largo de su vida, mientras que aquellas con la mutación BRCA2 tienen ~69 % de riesgo de sufrir lo mismo. Además, APAC se enfrenta al problema de la creciente prevalencia del cáncer. China, Japón, India, Taiwán, Corea del Sur, Malasia, Singapur, Tailandia, Filipinas, Sri Lanka, Vietnam, Indonesia, Mongolia, Laos y Camboya son los 15 principales países con una gran incidencia de cáncer. Según los datos del Instituto Nacional de Prevención e Investigación del Cáncer (NICPR), en 2018 el cáncer provocó 784.821 muertes en la India. Por lo tanto, la creciente prevalencia del cáncer impulsa el crecimiento constante del cáncer hereditario, impulsando así el crecimiento del mercado de pruebas de cáncer hereditario.
Perspectivas basadas en el tipo de diagnóstico
El mercado mundial de pruebas de cáncer hereditario, según el tipo de diagnóstico, se divide en biopsia e imágenes. El segmento de biopsias representó una participación mayor en 2018. Sin embargo, se espera que el segmento de imágenes experimente un crecimiento más rápido durante 2019-2027. Se espera que el segmento de biopsias crezca debido a la creciente prevalencia del cáncer, la creciente demanda de cirugías mínimamente invasivas, las iniciativas emprendidas por el gobierno y las autoridades. organizaciones de salud globales.
Información basada en tecnología
El mercado global de pruebas de cáncer hereditario, basado en tecnología, se segmenta en secuenciación, PCR y micromatriz. El segmento de secuenciación fue el más grande entre los subsegmentos de tecnología en 2018 y se espera que continúe experimentando un crecimiento significativo durante 2019-2027. Se espera que el segmento de secuenciación crezca debido a la asignación de fondos por parte de varios organismos gubernamentales y al uso de NGS en la secuenciación y secuenciación dirigida para múltiples propósitos, como la detección de cáncer hereditario.
Información basada en el usuario final
El mercado global de pruebas de cáncer hereditario, según el usuario final, está segmentado en centros de diagnóstico, hospitales y clínicas. Se espera que los centros de diagnóstico experimenten el mayor crecimiento durante el período previsto. Sin embargo, el segmento hospitalario representó la mayor proporción en 2018 y se espera que continúe con una tendencia similar durante el período previsto. Se espera que el segmento de centros de diagnóstico crezca debido al diagnóstico preciso y al riesgo reducido de prueba y diagnóstico. tratamiento de errores. Las pruebas genéticas ayudan a estimar las posibilidades de desarrollar cáncer en la vida mediante la búsqueda de mutaciones en genes, cromosomas o proteínas.
Los lanzamientos y aprobaciones de productos se adoptan comúnmente estrategias de las empresas para ampliar su huella global y sus carteras de productos. Además, los actores del mercado de pruebas de cáncer hereditario se centran en la estrategia de asociación para ampliar su clientela, lo que, a su vez, les permite mantener su marca en todo el mundo. Se prevé que la cuota de mercado de pruebas de cáncer hereditario florecerá con el desarrollo de nuevos productos innovadores por parte de los actores del mercado. Algunos actores que operan en el mercado son Hologic Inc.; Koninklijke Philips NV; Quest Diagnóstico incorporado; Myriad Genetics, Inc.; Genética Ambry; Laboratorios NeoGenómicos; Consejo; Cáncer Genética Inc.; Corporación Invitae; miógenos; Strand Life Sciences Pvt. Limitado. Limitado.; Corporación Pathway Genomics; y CENTOGENE AG.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.
In terms of end user, the global hereditary cancer testing market is segmented into diagnostic centers, hospital, and clinics. Among the above 4 segments, the diagnostic centers segment held the largest market share in 2018.
The hospital segment is estimated to grow at the fastest rate during the forecast period.
Problems in accessing whole genomic data for early detection is the major factor hindering the market growth.
The List of Companies
- Hologic Inc.
- Koninklijke Philips N.V.
- Quest Diagnostics Incorporated
- Myriad Genetics, Inc.
- Cancer Genetics Inc.
- Invitae Corporation
- Myogenes
- Strand Life Sciences Pvt. Ltd.
- Pathway Genomics Corporation
- CENTOGENE AG
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Sep 2019
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Sep 2019
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2019
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Sep 2019
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Sep 2019
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Sep 2019
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Sep 2019
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)